Given the genetic and pathophysiological evidence suggesting that deficiency in DAGLB-mediated 2-AG production contributes to the etiopathogenesis in PD, enhancing 2-AG transmission within the SN may present a viable therapeutic approach for the disease. The gene discussed is DAGLB; the disease is Parkinson disease.